Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review.
about
Haloperidol versus placebo for schizophreniaTrace Amines and the Trace Amine-Associated Receptor 1: Pharmacology, Neurochemistry, and Clinical ImplicationsThe Incidence of Akathisia in the Treatment of Schizophrenia with Aripiprazole, Asenapine and Lurasidone: A Meta-AnalysisBrain Histamine N-Methyltransferase As a Possible Target of Treatment for Methamphetamine OverdoseExtended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled studyAntipsychotic-like effects of a neurotensin receptor type 1 agonist.Behavioural and functional characterization of Kv10.1 (Eag1) knockout miceActivation of neurotensin receptor type 1 attenuates locomotor activity.Adolescent attitudes toward psychiatric medication: the utility of the Drug Attitude Inventory.Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163).Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data.Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.Augmentation of clozapine with aripiprazole in severe psychotic bipolar and schizoaffective disorders: a pilot study.Disease and drug effects on internally-generated and externally-elicited responses in first episode schizophrenia and psychotic bipolar disorder.Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy.The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression.Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for PsychopharmacologyNeurochemical Metabolomics Reveals Disruption to Sphingolipid Metabolism Following Chronic Haloperidol AdministrationPostural Stability of Patients with Schizophrenia during Challenging Sensory Conditions: Implication of Sensory Integration for Postural Control.Subthreshold bipolarity: diagnostic issues and challengesComparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder.An Untargeted Metabolomics Analysis of Antipsychotic Use in Bipolar DisorderNumber needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics.Behavioral and emotional adverse events of drugs frequently used in the treatment of bipolar disorders: clinical and theoretical implications.Persistent akathisia masquerading as agitated depression after use of ziprasidone in the treatment of bipolar depressionChronic Nicotine Mitigates Aberrant Inhibitory Motor Learning Induced by Motor Experience under Dopamine Deficiency.Should psychiatrists use atypical antipsychotics to treat nonpsychotic anxiety?Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology.A review of the safety and tolerability of aripiprazole.Epilepsy and bipolar disorders.Risperidone long-acting injection as monotherapy and adjunctive therapy in the maintenance treatment of bipolar I disorder.Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder.State of the art: treatment of bipolar disorders.Pharmacokinetic evaluation of armodafinil for the treatment of bipolar depression.Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.Second-generation antipsychotics in the treatment of major depressive disorder: current evidence.Important clinical features of atypical antipsychotics in acute bipolar depression that inform routine clinical care: a review of pivotal studies with number needed to treatIs there a 'weight neutral' second-generation antipsychotic for bipolar disorder?Bipolar affective disorder and Parkinson's disease.Antipsychotic-induced catalepsy is attenuated in mice lacking the M4 muscarinic acetylcholine receptor.
P2860
Q24202457-496D4649-466E-4055-8F64-A08C64105414Q26752602-DC5D53F2-92ED-4107-B61E-0D370EEF17C7Q26782978-DFDBEFB0-E024-45BD-A17D-39F01F7D5B14Q28067373-38245838-820A-497B-BD08-D903C2698050Q28254377-EF97C717-CDD5-459E-8F44-4AED94A4509CQ30356261-C257653F-E13E-4449-B393-C08AEF034FFDQ30454673-4C750D5B-659A-4A95-B882-C032E5356F4FQ30584554-3CE4A140-CD62-41A4-A1E7-146EBEE6C100Q33583484-906A3944-6615-429A-A523-CEB085A5FA36Q33587032-3682BAF0-D54A-4AC1-9EB6-183D270504A9Q33799660-67A2F969-F057-4DB7-9CB0-9F7D7B890E50Q33878816-776BFAAA-DED0-48FD-8F1E-2BE1C5F87FE4Q34002264-39483FE0-FFFC-48B9-BAF2-C5FBF6F50D72Q34254441-0814B2F7-AA4B-4ADD-8574-7E99D2B8047BQ34259426-FD8B633B-BF2C-4BF1-A91A-01FC003B0523Q34616633-66A33A02-7739-4DF0-8F51-401FE610F33CQ34676317-FF51C321-7793-402A-BE24-903907D419B7Q35987580-53FDD263-6278-41A6-9FD0-70E0DD07EF46Q36064066-2845D4CC-04FE-453F-9C6C-D4D2C885A5E8Q36096615-16182C13-7B61-48CB-8438-F8CF35897F7CQ36208776-F7510C18-52A3-484E-BD37-A999B8989AAEQ36225284-57BEAA85-15CE-48E4-BDBF-D75C01891C56Q36275903-3D8CF6E7-068B-408A-B92A-3A46C5444642Q36582018-BD443CAB-9F03-46CF-8A53-13DBAA659F44Q36755045-719B2509-EA47-4FF1-875F-AB597E548E93Q36889608-F4CB9618-86F9-4BF4-B647-CA22B03513CDQ37289300-9EAB3F80-69EC-4682-9E8E-1787AE60B0C1Q37426143-82DC2350-1C2F-4035-8DD9-EC1A9FA3470BQ37510958-83646E49-FF24-400F-9552-A489611EFEDFQ37658892-5F7A6ED7-D81B-461F-82E5-19E64F503BEFQ37756971-C7819507-EBA7-4294-95C6-AA0368268B44Q37803220-49133BB0-E0CA-47BB-A338-1CCC2252DD0DQ37954416-522E9A1D-3E5E-4E02-BC88-B3FC9FE43580Q38026866-AAD6FC47-193B-4861-AB91-90D51083138AQ38042478-9450BE2B-959D-4C85-AFFE-6E0BCF276AE9Q38125219-5A5E9088-8219-4A40-B59B-1DA3B25F2347Q38507842-4B4FD0B5-B47A-4A77-BA39-A71D4B7BBF41Q39049252-C81AAAA4-7291-4A51-B876-CB359ACBCF0CQ39455953-4D2B445F-BD97-40EB-B8AB-5D0F64FDC1C7Q39789571-6422D4B1-7CF9-4F74-9596-75FC9E16DD9D
P2860
Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antipsychotic-induced extrapyr ...... ophrenia: a systematic review.
@en
Antipsychotic-induced extrapyr ...... ophrenia: a systematic review.
@nl
type
label
Antipsychotic-induced extrapyr ...... ophrenia: a systematic review.
@en
Antipsychotic-induced extrapyr ...... ophrenia: a systematic review.
@nl
prefLabel
Antipsychotic-induced extrapyr ...... ophrenia: a systematic review.
@en
Antipsychotic-induced extrapyr ...... ophrenia: a systematic review.
@nl
P2093
P2860
P1476
Antipsychotic-induced extrapyr ...... ophrenia: a systematic review.
@en
P2093
David E Kemp
Joseph R Calabrese
Keming Gao
Prashant Gajwani
Stephen J Ganocy
P2860
P304
P356
10.1097/JCP.0B013E318166C4D5
P407
P50
P577
2008-04-01T00:00:00Z